The trajectory of Sildenafil presents a nuanced case for investors in the pharmaceutical sector. While initially a phenomenal success, producing vast sums, the patent expiration and the subsequent entry of generic alternatives have significantly affected earnings. This poses questions about the future profitability of related therapeutic developmen